Effects of a low dose esketamine adjunct to propofol sedation with sufentanil during cervical conization

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040457

Enrollment

Unknown

Registered

2020-11-28

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical intraepithelial neoplasia

Interventions

Group S:Propofol and sufentanil

Group ES:Propofol and esketamine and sufentanil

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 60 years old; ASA class I to II; BMI < 30; Stop-bang < 3

Exclusion criteria

Exclusion criteria: Angina pectoris and myocardial infarction occurred within 6 months; Congestive heart failure; Untreated or poorly controlled hypertension (SBP > 180mmHg, DBP > 100 mmHg); History of central nervous system, history of mental illness, intracranial hypertension; Glaucoma; Patients with hyperthyroidism and oral thyroxine tablets; Severe liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
Respiratory related adverse sedation event;	—

Secondary

Measure	Time frame
patient satisfaction;doctor satisfaction;	—

Countries

China

Contacts

Public ContactJiguo Si

Zibo Central Hospital

43254465@qq.com+86 18678186929

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026